Pfizer Consumer Healthcare To Expand Caltrate And Centrum Production In China

Pfizer Consumer Healthcare To Expand Caltrate And Centrum Production In China

SUZHOU, China--(BUSINESS WIRE)--Pfizer Inc. (PFE) announced today that it broke ground for a $95 million consumer products production facility in Suzhou, China. The new site is near the company's existing Suzhou site and will help increase production capacity to meet growing demand for Pfizer Consumer Healthcare's brands in China and the Asia-Pacific region.

"Asia Pacific is a large and rapidly growing region for Pfizer Consumer Healthcare and our new plant in Suzhou will give us the production capacity we need to meet increasing demand for our brands, particularly in China," said Andy Schmeltz, Regional President, Asia Pacific and Europe, Middle East and Africa, Pfizer Consumer Healthcare.

The new facility will primarily produce Caltrate® dietary supplements and Centrum® multivitamins, and in the future will support production of additional products. There are also plans to eventually house a research and development facility on the site to help support innovation in the region.

The site design is expected to achieve Leadership in Energy and Environmental Design (LEED) certifications, and will incorporate the most advanced technologies to minimize energy and water consumption.

For instance, to minimize energy consumption, the plant will be fitted with high-efficiency manufacturing equipment, LED and solar powered lighting with automatic controls. It will employ technologies to recycle waste heating and cooling and will make extensive use of natural lighting and shading. To conserve water, the plant will use high efficiency equipment and fixtures, recycle treated wastewater for its cooling tower and for toilets and capture rain water for irrigation of its lawn and landscaping.

"This new site is the latest step on our journey of environmental sustainability," said Tony Maddaluna, Executive Vice President and President of Pfizer Global Supply. "For 15 years, we have voluntarily met or exceeded the public goals we have set to reduce our greenhouse gas emissions globally. This new facility is in keeping with that commitment to environmental stewardship."

Pfizer in Suzhou

The Pfizer Suzhou facility began production in 1994, and since then has implemented a number of expansion projects to keep pace with double-digit growth in demand for Caltrate and Centrum. The existing Suzhou facility employs about 700 colleagues, and produces Centrum multivitamins, Caltrate dietary supplements, Robitussin® cough and cold products, antibiotics as well as other prescription and over-the-counter products. It supplies multiple countries in the Asia Pacific region, including China.

"We are pleased to build on the strong foundation we have in Suzhou, where we have produced consumer healthcare and prescription products for more than twenty years," said Keith Choy, Regional General Manager, North Asia, Pfizer Consumer Healthcare. "We are confident that as we expand with a new site here, we will build on the productive and mutually beneficial relationships we have developed with the community.

Pfizer in China

Pfizer has been doing business in China since the 1980s and employs approximately 10,000 colleagues there, with approximately 1,400 working in Pfizer Consumer Healthcare. Currently, Pfizer operates in 300 cities throughout China, has three other production facilities in the country in addition to its operations in Suzhou, and operates two world-class research and development centers in China. To learn more, please visit

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at

DISCLOSURE NOTICE: The information contained in this release is as of June 15, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information related to the development of a new production facility in China by Pfizer, including Pfizer's plans and prospects for the production facility and its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the timely completion of the production facility or at all; risks related to the ability to realize the anticipated benefits of the production facility, including the possibility that the expected benefits from the proposed production facility will not be realized or will not be realized within the expected time period; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange or interest rates; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at and


View source version on